Related Experiment Video

Updated: Jun 23, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Novel therapeutics for the treatment of metastatic melanoma

Aaron S Mansfield1, Svetomir N Markovic

  • 1Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. mansfield.aaron@mayo.edu

Future Oncology (London, England)
|May 20, 2009
PubMed

Insights

Metastatic malignant melanoma remains incurable, with limited survival rates. This review explores novel therapeutic strategies, including immunotherapy and targeted agents, to improve outcomes for patients with advanced melanoma.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Metastatic malignant melanoma has a poor prognosis, with a median survival of 8.5 months and a 5-year survival rate below 5%.
  • Current FDA-approved systemic therapies (hydroxyurea, dacarbazine, interleukin-2) have not significantly improved survival endpoints for metastatic melanoma patients.
  • There is a critical need for innovative therapeutic strategies to enhance outcomes in advanced melanoma.

Purpose of the Study:

  • To review recent advances in novel therapeutic developments for metastatic malignant melanoma.
  • To highlight innovative strategies aimed at improving survival and treatment efficacy for advanced melanoma.

Main Methods:

  • Literature review of recent advances in melanoma treatment.
  • Focus on immune therapy, tyrosine kinase inhibitors, and angiogenesis inhibitors.
  • Synthesis of current research on novel therapeutic developments.

Main Results:

  • Several innovative therapeutic strategies are under investigation for metastatic melanoma.
  • Emerging treatments include immune therapies, tyrosine kinase inhibitors, and angiogenesis inhibitors.
  • These novel approaches show promise for improving patient outcomes.

Conclusions:

  • Novel therapeutic strategies offer new hope for treating metastatic malignant melanoma.
  • Continued research into immunotherapy, tyrosine kinase inhibitors, and angiogenesis inhibitors is crucial.
  • These advancements may lead to improved survival rates and better quality of life for melanoma patients.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...